Figure 3From: MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancerCombination of Nutlin-3a and the anti-androgen casodex. Exponentially growing LNCaP, 22Rv1, and DU145 were treated with 10 μM casodex (CDX) and/or 5 μM Nutlin-3a in the presence of complete serum or CSS and apoptotic fraction determined by the Annexin V assay ± SD.Back to article page